Turn Therapeutics Announces Interim Analysis Findings From First 50 Completed Subjects Enrolled In Ongoing Randomized, Double-Blind, Vehicle-Controlled Phase 2 Clinical Trial Evaluating GX-03 In Adults With Atopic Dermatitis
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Turn Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Q4 EPS $0.01
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock
D. Boral Capital Maintains Buy on Turn Therapeutics, Maintains $8 Price Target
Turn Therapeutics shares are trading higher after the company announced corporate, financial, and pipeline updates ahead of the 2026 J.P. Morgan Healthcare Conference.
Turn Therapeutics Advances GX-03 Phase 2 Program, Expands Vaccine Pipeline; Targets Initial Commercial Revenue In 2026
Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buying
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
D. Boral Capital Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $8
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Q3 EPS $(0.07) vs $(0.03) Prior
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
